ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On February 16, 2017, Ultragenyx Pharmaceutical Inc. issued a
press release announcing its financial results for the three
months ended December 31, 2016 and the year ended December 31,
2016 (the Press Release).A copy of the Press Release is furnished
herewith as Exhibit 99.1.
The information set forth under Item 2.02 and in Exhibit 99.1
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, except as shall be expressly set forth by specific
reference in such filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release, dated February 16, 2017 |
|
* |
** |
About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy. ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Recent Trading Information
ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) closed its last trading session up +0.06 at 76.82 with 432,478 shares trading hands.
